31.05.2015 16:20:11
|
Curis: CUDC-907 Shows Evidence Of Clinical Activity With Objective Responses
(RTTNews) - Curis Inc. (CRIS) reported results from the completed dose escalation and ongoing expansion stages of a Phase 1 trial of CUDC-907, an oral dual inhibitor of histone deacetylase and phosphoinositide 3-kinase enzymes. The company said, at the recommended Phase 2 dose and schedule, CUDC-907 has demonstrated evidence of clinical activity with objective responses observed in patients with relapsed/ refractory diffuse large B cell lymphoma and Hodgkin's lymphoma.
After completing the expansion arms of the ongoing trial in patients with relapsed/ refractory diffuse large B cell lymphoma treated with CUDC-907 either as monotherapy or in combination with rituximab, the company expects to initiate a registration directed Phase 2 study in the patient population later in the current year.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Curis, Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |